Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Artavazd Arumov Ph.D
Principal
Ryan Baker
CFO
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Isaac Ciechanover
Partner
Phil DiGiacomo
Principal
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Co-Founder and Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Will McConnell
Principal
Gary Rieschel
Founder and Managing Partner
James Shen
Venture Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Rachel Wang
Venture Partner
James Wang
Venture Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Oscar Zhang
Principal
Yafeng Zhou
Associate
Alex Zhou
Managing Partner
Zhiyuan Zhou
Associate
Zhifeng Zhou
Managing Partner
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Phillip DiGiacomo Ph.D
Principal
Past deals in Medical Devices
Weimei Health
Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology
Singular Medical
Series C in 2025
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
TOPI Imaging Technology
Series E in 2025
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.
Pulnovo Medical
Series C in 2025
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Nanos Medical
Venture Round in 2025
Nanos Medical specializes in the research, development, manufacturing, and sales of disposable medical devices, primarily targeting the cardiovascular and ear, nose, and throat (ENT) fields. The company offers a range of innovative products, including sinus balloon catheters, eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal balloons, and drug-eluting stents for sinus applications. Through its advanced medical devices, Nanos Medical aims to enhance treatment options for hospitals and patients, contributing to improved healthcare outcomes.
Xi'an Dunbo Medical Equipment
Series A in 2025
Xi'an Dunbo Medical Equipment focuses on the research, development, and production of AI medical devices. The products currently under development are cardiac pacemakers and brain pacemakers, Cardiac defibrillators. Self-developed products include chips, hardware circuits, software application systems, and structural materials.
Xinzeyuan
Series B in 2025
Xinzeyuan Medical is a manufacturer specializing in precision components and consumables for medical endoscopes. The company focuses on producing minimally invasive surgical instruments and various medical consumables, aimed at enhancing the safety and efficiency of surgical treatments for medical professionals. By delivering high-quality products, Xinzeyuan Medical plays a vital role in supporting healthcare providers and improving patient outcomes.
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Dearer Medical
Venture Round in 2024
Dearer Medical is a medical device company based in China that specializes in the development, production, and sales of eye-related products, particularly contact lenses. The company emphasizes research and development to create both practical and fashionable color contact lenses, catering to a diverse customer base. Through its innovative approach, Dearer Medical aims to enhance the user experience while addressing the aesthetic and functional needs of contact lens wearers.
IntoCare
Series D in 2024
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
SinoUnited Health
Series D in 2024
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
CSR Biotech
Series A in 2024
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
SonoSilicon
Angel Round in 2024
SonoSilicon researches on medical-grade micro-on-chip ultrasound systems and chip design and promotes the medical device industry.
DK Medtech
Series E in 2024
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
Thorough Future
Series A in 2024
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.
CureGenetics
Series B in 2024
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
ACXEL
Series A in 2024
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Inexbot
Series A in 2023
iNexBot specializes in the development and manufacturing of robot motion controllers and industrial robot intelligence technology. The company focuses on creating solutions for various sectors, including industrial robotics, collaborative robotics, semiconductors, healthcare automation, and automotive electronics. iNexBot's offerings encompass advanced robot motion control systems, machine vision technology, laser seam tracking technology, and other essential robot hardware. By providing both hardware and software, iNexBot equips robot manufacturers with the necessary tools to enhance their robotic products and improve operational efficiency across multiple industries.
CSR Biotech
Series A in 2023
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
Saints & Sages
Series B in 2023
Saints & Sages Medical specializes in the production and sale of minimally invasive surgical medical devices. The company offers a range of energy device products utilized across various medical fields, including hepatobiliary surgery, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. By closely monitoring clinical needs, Saints & Sages is committed to developing innovative surgical devices that enhance the accuracy and efficiency of procedures. The company is supported by a dedicated research and development team with extensive experience in clinical transformation, allowing it to continually advance its offerings to better serve patients worldwide.
Atantares
Seed Round in 2023
Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Thorough Future
Series A in 2023
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.
IntoCare
Series D in 2023
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
DK Medtech
Venture Round in 2023
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
Ricoton
Series A in 2023
Ricoton specializes in the development and production of medical devices aimed at treating or preventing cerebrovascular diseases. Founded in 2011 and based in Hunan, China, the company manufactures an array of intervention devices, including microcatheters, guidewires, and various tools for ischemic stroke treatment. Their product offerings feature a comprehensive three-piece set that includes a micro guide wire, micro catheter, and support catheter for vascular access, as well as a thrombectomy stent and balloon guide catheter. Ricoton's innovative solutions provide a one-stop thrombectomy option for patients, enhancing the effectiveness of cerebrovascular interventions.
SinoUnited Health
Series C in 2023
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
Hochuen Medical
Series B in 2023
Hochuen Medical USA Corp. is a manufacturer of medical devices and consumables, specializing in In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices. Established in 2015 by Dr. Robin Liu and Eric Zeng, the company operates as an OEM/ODM manufacturer, providing services that range from product design and development to mass production. Hochuen Medical's product offerings include essential healthcare items such as COVID-19 testing kits, microfluidic biochips, and various medical disposables. The company is recognized for its commitment to quality, holding FDA registration and ISO certifications, and emphasizes research and development to offer innovative solutions for the healthcare sector. With a founding management team that possesses extensive experience in manufacturing and development, Hochuen Medical aims to address the evolving needs of medical professionals and patients through its diverse product portfolio.
Tingsheng Technology
Series B in 2023
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Singular Medical
Series B in 2023
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Shennapsi Artificial Intelligence Technology
Series A in 2022
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Newsoara
Venture Round in 2022
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
Fitlens
Series B in 2022
Fitlens is a company that provides ophthalmic medical treatment. They specialize in the design and manufacture of high-end, complicated optical contact lenses as well as the design and manufacture of high-end intraocular lens optical molds.
PureVision
Series A in 2022
PureVision focuses on developing medical devices for ophthalmology. PureVision was founded in 2022 and was headquartered in Wenzhou, Zhejiang China.
Thorough Future
Series A in 2022
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.
CSR Biotech
Seed Round in 2022
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
KouTech
Series A in 2022
KouTech develops surgical robots that can perform ophthalmic surgery, trans-gastroscopic, and general-purpose microsurgery. KouTech was founded in 2022 and was headquartered in Shanghai, China.
GYENNO Technologies
Series B in 2022
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
Norm Medtech
Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.
Atantares
Angel Round in 2022
Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.
Gaugene
Series B in 2022
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.
Purevision
Seed Round in 2022
Purevision is a technological start-up company that focuses on innovative ophthalmic medical devices.
Yike Polymers
Series B in 2022
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Vistel
Series B in 2022
Vistel is a technology company founded in 2016 by Sun Yuhui and Ding Dayong, specializing in the application of artificial intelligence in the medical field. The firm focuses on developing AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By utilizing advanced diagnostic systems that incorporate computer vision processing and image annotation, Vistel aims to provide medical practitioners with innovative tools for the digital analysis and management of patients' eye conditions.
ACXEL
Seed Round in 2022
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.
Tingsheng Technology
Series A in 2022
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
CureGenetics
Series B in 2022
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Cornerstone Robotics
Series B in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Tripod Preclinical Research
Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.
Genedit
Angel Round in 2021
GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.
GYENNO Technologies
Series B in 2021
GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.
Berry Oncology
Series B in 2021
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Zion Pharma
Series B in 2021
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Hochuen Medical
Series A in 2021
Hochuen Medical USA Corp. is a manufacturer of medical devices and consumables, specializing in In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices. Established in 2015 by Dr. Robin Liu and Eric Zeng, the company operates as an OEM/ODM manufacturer, providing services that range from product design and development to mass production. Hochuen Medical's product offerings include essential healthcare items such as COVID-19 testing kits, microfluidic biochips, and various medical disposables. The company is recognized for its commitment to quality, holding FDA registration and ISO certifications, and emphasizes research and development to offer innovative solutions for the healthcare sector. With a founding management team that possesses extensive experience in manufacturing and development, Hochuen Medical aims to address the evolving needs of medical professionals and patients through its diverse product portfolio.
Insight Lifetech
Series D in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
LetsGetChecked
Series D in 2021
LetsGetChecked is a healthcare technology company that facilitates at-home health testing. It connects users with regulated laboratories worldwide for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Users collect samples at home using provided kits and mail them back for analysis; results are then accessible online. The platform aims to empower individuals to proactively manage their health, offering services across the United States, Canada, and Europe.
BrainHealth
Series C in 2021
BrainHealth focuses on the research and development, production, and sales of neurological medical equipment.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Insight Lifetech
Secondary Market in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Health Biotech
Series B in 2021
Health Biotech is a research and development firm specializing in precision medicine through the application of mass spectrometry. The company focuses on early diagnosis, treatment, and monitoring of Alzheimer's disease, employing liquid chromatography-mass spectrometry techniques to quantitatively detect specific biomarkers associated with the condition. By offering comprehensive solutions that include tools, equipment, and reagent consumables, Health Biotech aims to provide reliable detection services for patients. Its innovative technology not only aids in identifying risks for Alzheimer's disease but also supports healthcare professionals in enhancing patient outcomes by delaying disease onset and improving cognitive abilities.
Just Medical
Series B in 2021
Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.
SinoUnited Health
Series C in 2021
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
Gaugene
Series A in 2021
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.
Zion Pharma
Series B in 2021
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Delta Medical
Series E in 2021
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
IntoCare
Secondary Market in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Newsoara
Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
Saints & Sages
Series A in 2021
Saints & Sages Medical specializes in the production and sale of minimally invasive surgical medical devices. The company offers a range of energy device products utilized across various medical fields, including hepatobiliary surgery, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. By closely monitoring clinical needs, Saints & Sages is committed to developing innovative surgical devices that enhance the accuracy and efficiency of procedures. The company is supported by a dedicated research and development team with extensive experience in clinical transformation, allowing it to continually advance its offerings to better serve patients worldwide.
Singular Medical
Series B in 2021
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Vistel
Series B in 2021
Vistel is a technology company founded in 2016 by Sun Yuhui and Ding Dayong, specializing in the application of artificial intelligence in the medical field. The firm focuses on developing AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By utilizing advanced diagnostic systems that incorporate computer vision processing and image annotation, Vistel aims to provide medical practitioners with innovative tools for the digital analysis and management of patients' eye conditions.
Cornerstone Robotics
Series A in 2021
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Insight Lifetech
Series C in 2020
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
MicroTech Medical
Series D in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
dMed
Series C in 2020
dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.
Compart Systems
Venture Round in 2020
Compart Systems, established in 2016, is a precision engineering company that manufactures and supplies high-precision metal components. Based in Singapore with offices in Austin, Texas; Shenzhen, China; and Hwasung-Si, South Korea, the company specializes in flow control products and technologies. Its portfolio includes VCR and microfit fittings, valves, regulators, filters, transducers, and mass flow controllers, catering to the semiconductor, industrial, and medical industries.
Elevation Oncology
Series B in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.
Broncus Medical
Series C in 2020
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.
MEDx
Series B in 2020
MEDx is a company specializing in precision medicine solutions aimed at enhancing clinical development. Founded in 2013 and headquartered in Suzhou, Jiangsu, MEDx employs translational science to advance diagnostic technologies related to nucleic acids and proteins. Its comprehensive services include biomarker development, Companion Diagnostics, Point-of-Care development, clinical testing, and the commercialization of medical products. By focusing on individualized treatment, MEDx seeks to improve patient outcomes through its innovative approaches in the healthcare sector.
Delta Medical
Series D in 2020
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
Zion Pharma
Series A in 2020
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Elevation Oncology
Series A in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.
New Horizon Health
Series E in 2020
New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.
LetsGetChecked
Series C in 2020
LetsGetChecked is a healthcare technology company that facilitates at-home health testing. It connects users with regulated laboratories worldwide for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Users collect samples at home using provided kits and mail them back for analysis; results are then accessible online. The platform aims to empower individuals to proactively manage their health, offering services across the United States, Canada, and Europe.
MicroTech Medical
Venture Round in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
New Horizon Health
Series D in 2020
New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.
DiNovA Medtech
Series C in 2020
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.
Bioscience
Venture Round in 2020
Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.
Shulan Health
Series C in 2020
Shulan Health operates a hospital center focused on enhancing patient well-being through a range of healthcare services. These services include rehabilitation, nutrition, health examinations, and remote consultations, all designed to meet the diverse needs of patients. The facility adheres to accredited international medical standards, ensuring high-quality care. By integrating advanced IT technology, Shulan Health aims to deliver a personalized and holistic healthcare experience, contributing significantly to the overall health outcomes of its patients.
CureGenetics
Series A in 2020
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Singular Medical
Series A in 2020
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Berry Genomics
Post in 2020
Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.
Berry Oncology
Series A in 2020
Berry Oncology is a medical technology company focused on enhancing cancer prevention and diagnosis through advanced genomic testing solutions. The company offers a range of products and services, including genetic diagnosis, companion diagnostics, and tools for monitoring treatment response and prognosis prediction for various malignant tumors. By addressing clinical challenges associated with cancer detection and management, Berry Oncology aims to facilitate early diagnosis and treatment, ultimately improving patient quality of life and reducing cancer risks. Its mission emphasizes precise treatment for all patients, while its vision seeks to establish the company as a leader in early screening and diagnosis within the global market, particularly in China's tumor gene testing sector.
Element Science
Series C in 2020
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
SinoUnited Health
Series C in 2019
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.
DiNovA Medtech
Series C in 2019
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.
Newsoara
Series B in 2019
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.